VanEck Pharmaceutical ETF

Frequently Asked Questions About PPH

What does PPH invest in?

VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

What is the expense ratio of PPH?

VanEck Pharmaceutical ETF (PPH) charges an expense ratio of 0.36%. This is the annual fee deducted from fund assets to cover management and operations.

How big is PPH?

VanEck Pharmaceutical ETF (PPH) manages $1.05B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is PPH actively managed or an index fund?

PPH's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was PPH launched?

VanEck Pharmaceutical ETF (PPH) launched in December 2011 and is managed by VanEck.

How has PPH performed?

PPH's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.